South Rampart Pharma is an early-stage, asset-centric life sciences company developing novel first-in-class small molecules for the treatment of acute and chronic pain, as well as fever.
We have synthesized and characterized new molecules that reduce fever and treat pain without the risk of liver toxicity. Because our class of molecules are not opioids, they will not have risks of misuse and dependence.
Pre-clinical in vitro and in vivo animal model data demonstrate that these molecules are analgesic (pain-reducing) and antipyretic (fever-reducing), while devoid of the hepatotoxicity (liver) and nephrotoxicity (kidney) present in common over the counter medications, such as acetaminophen and NSAIDs (non-steroidal anti-inflammatory drugs). Moreover, we have identified the mechanisms for the lack of liver toxicity.
Hepatic tight junctions demonstrating the classic ‘chicken wire’ configurations (ZO-1 staining) are maintained in liver sections from an in vivo animal model treated with our novel analgesic and anti-pyretic compounds
